Top-Rated StocksTop-RatedNASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis $3.77 -0.22 (-5.51%) Closing price 04:00 PM EasternExtended Trading$3.78 +0.00 (+0.13%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Taysha Gene Therapies Stock (NASDAQ:TSHA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Taysha Gene Therapies alerts:Sign Up Key Stats Today's Range$3.75▼$4.1350-Day Range$3.51▼$5.1652-Week Range$3.45▼$7.30Volume2.17 million shsAverage Volume3.09 million shsMarket Capitalization$1.23 billionP/E RatioN/ADividend YieldN/APrice Target$12.75Consensus RatingBuy Company Overview Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company’s lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha’s research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy. Taysha’s therapies remain under development and are not established treatments. The company’s work centers on advancing these programs through clinical research and regulatory review.AI Generated. May Contain Errors. Read More Taysha Gene Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreTSHA MarketRank™: 1.89615174672 of 5 starsTaysha Gene Therapies scored higher than 38% of companies evaluated by MarketBeat, and ranked 1253rd out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTaysha Gene Therapies has a consensus price target of $12.75, representing about 238.8% upside from its current price of $3.76.Amount of Analyst CoverageTaysha Gene Therapies has only been the subject of 2 research reports in the past 90 days.Read more about Taysha Gene Therapies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Taysha Gene Therapies are expected to grow in the coming year, from ($0.45) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.00% of the float of Taysha Gene Therapies has been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 14.76, which indicates bearish sentiment.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 4.35%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.19 News SentimentTaysha Gene Therapies has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows5 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders3.48% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Taysha Gene Therapies' insider trading history. Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TSHA Stock News HeadlinesTaysha Gene Therapies (NASDAQ:TSHA) Upgraded at Wall Street ZenNovember 17 at 3:23 AM | americanbankingnews.comTaysha (TSHA) Q3 2026 Earnings Call TranscriptNovember 13, 2026 | finance.yahoo.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 19 at 1:00 AM | Behind the Markets (Ad)Taysha Gene Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMTaysha Gene Therapies' Q3 Net Loss WidensNovember 12, 2026 | marketscreener.comMTaysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 12, 2026 | globenewswire.comTaysha Gene Therapies Q3 2026 earnings previewNovember 11, 2026 | msn.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 6, 2026 | globenewswire.comSee More Headlines TSHA Stock Analysis - Frequently Asked Questions How have TSHA shares performed this year? Taysha Gene Therapies' stock was trading at $5.50 at the beginning of the year. Since then, TSHA stock has decreased by 31.6% and is now trading at $3.7630. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) issued its quarterly earnings data on Thursday, November, 12th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.03. Read the conference call transcript. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $150 million in an IPO on Thursday, September 24th 2020. The company issued 7,869,566 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Taysha Gene Therapies' top institutional shareholders include RA Capital Management L.P. (9.34%), Goldman Sachs Group Inc. (7.71%), State Street Corp (3.49%) and Pictet Asset Management Holding SA (1.02%). Insiders that own company stock include Sean P Nolan, Paul B Manning, Kamran Alam and Sukumar Nagendran. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Taysha Gene Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Micron Technology (MU), Tesla (TSLA), Plug Power (PLUG) and SoFi Technologies (SOFI). Company Calendar Last Earnings11/12/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 9 days, TSHA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TSHA CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees99Year Founded2020Price Target and Rating Average Price Target for Taysha Gene Therapies$12.75 High Price Target$17.00 Low Price Target$10.00 Potential Upside/Downside+238.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$109 million Net MarginsN/A Pretax Margin-2,844.63% Return on Equity-51.87% Return on Assets-40.29% Debt Debt-to-Equity Ratio0.13 Current Ratio18.56 Quick Ratio18.56 Sales & Book Value Annual Sales$5.49 million Price / Sales223.68 Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book3.45Miscellaneous Outstanding Shares326,046,000Free Float314,700,000Market Cap$1.23 billion OptionableOptionable Beta1.36 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:TSHA) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredAlpha Oracle Signal drops to $7 for Black FridayThe Alpha Oracle Signal trading system is on sale for just $7 during a limited Black Friday deal. Others paid ...TradeWins | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.